Clinical trials: Irritable Mood
Irritable Bowel Syndrome
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
- Trial name
- NCT01545037
- Testing
- L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
- Where
- 3 sites in United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Bio-K Plus International Inc.
Irritable Bowel Syndrome, Constipation
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C).
- Trial name
- RENEW-IBS-C (NCT07545772)
- Testing
- LY3537031
- Where
- 70 sites in United States, Belgium and 6 more
- Volunteers
- 342 people
- Sponsor
- Eli Lilly and Company
Irritable Colon
Sb-705498 Rectal Pain Study
SB-705498 has demonstrated efficacy in several preclinical and human experimental pain models. This study will investigate the efficacy of SB-705498 in patients with rectal pain.
- Trial name
- NCT00461682
- Testing
- SB-705498
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Diarrhea-predominant Irritable Bowel Syndrome
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the efficacy and safety of YM060 once daily for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) for a long-term period (up to 52 weeks).
- Trial name
- NCT01736423
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 151 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
This study will explore the safety and effectiveness of different doses of AGN 203818 in relieving Irritable Bowel Syndrome pain. The study is being conducted in 2 parts.
- Trial name
- NCT00441766
- Testing
- AGN 203818
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- Allergan
Irritable Bowel Syndrome, IBS
Study of Bacteria on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome
The purpose of this study is to determine whether probiotic bacterium Bifidobacterium longum (B. longum) can improve mood and bowel symptoms in patients with Irritable bowel syndrome (IBS).
- Trial name
- NCT01276626
- Testing
- Bifidobacterium longum, Maltodextrin
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Société des Produits Nestlé (SPN)
Irritable Bowel Syndrome
Alpha-galactosidase Enzyme and Irritable Bowel Syndrome
The purpose of this study is to determine whether alpha-galactosidase enzyme is affective in alleviating the symptoms of irritable bowel syndrome (IBS).
- Trial name
- ALFA (NCT01243853)
- Testing
- Alpha-galactosidase
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Verman Oy Ab
Irritable Bowel Disease
Assessing Uniqueness of Inflammatory Bowel Disease Related Microbiome-derived Biomarkers
To assess the differential expression of IBD-related microbiome-derived biomarkers including bacterial strains and peptides such as antimicrobial peptides (AMP) found in inner-colonic samples (HygiSample™) in comparison to home…
- Trial name
- NCT05640583
- Testing
- Hygieacare System
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- HyGIeaCare, Inc.
IBS - Irritable Bowel Syndrome
L. Casei DG® in Patients With Irritable Bowel Syndrome.
To assess the effect of L. casei DG® (Lactobacillus paracasei CNCMI1572; Enterolactis® plus) on abdominal symptoms and gut microbiota metabolism/composition in non constipated patients with IBS (Irritable Bowel Syndrome).
- Trial name
- PROBE2 (NCT03449628)
- Testing
- L.casei DG
- Where
- 20 sites in Italy
- Volunteers
- 264 people
- Sponsor
- SOFAR S.p.A.
Irritable Bowel Syndrome With Constipation (IBS-C)
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.
- Trial name
- NCT06553547
- Testing
- Tenapanor
- Where
- 20 sites in United States
- Volunteers
- 72 people
- Sponsor
- Ardelyx
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Pain
Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid
Irritable Bowel Syndrome (IBS) is a gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits in the absence of any organic cause.
- Trial name
- NCT01449487
- Testing
- PPC-5650
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Aros Pharma ApS
Irritable Bowel Syndrome
Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study
The purpose of this study is to evaluate the efficacy of a treatment with Lactobacillus casei DG in the reduction of the painful symptoms in patients affected by irritable bowel syndrome.
- Trial name
- NCT02077699
- Testing
- Lactobacillus casei DG
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- SOFAR S.p.A.
Irritable Bowel Syndrome
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study.
- Trial name
- NCT06206265
- Testing
- TRYP-0082, Psychotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- TRYP Therapeutics
Irritable Bowel Syndrome
Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide
A study to evaluate, by country and overall, the changes from baseline of the irritable bowel syndrome quality of life (IBS QoL) total score after 4 and 8 weeks of treatment with Duspatalin® or Dicetel® in IBS patients.
- Trial name
- NCT01678781
- Where
- 24 sites in China, Egypt and 2 more
- Volunteers
- 607 people
- Sponsor
- Abbott
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.
- Trial name
- NCT00394173
- Testing
- DNK333
- Where
- 43 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Novartis
Irritable Bowel Syndrome
Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome
The purpose of this study was to determine the dose-ranging efficacy and safety profile of encapsulated Bifidobacterium infantis 35624 in female subjects with irritable bowel syndrome (IBS).
- Trial name
- NCT00135031
- Testing
- Bifidobacterium infantis 35624
- Where
- 20 sites in United Kingdom
- Volunteers
- 362 people
- Sponsor
- Procter and Gamble